• 1
    Murthy R,Nunez R,Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005; 25( suppl 1): S41S55.
  • 2
    Lau WY,Ho S,Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998; 40: 583592.
  • 3
    Dancey JE,Shepherd FA,Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000; 41: 16731681.
  • 4
    Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004; 10: S107S110.
  • 5
    Geschwind JF,Salem R,Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004; 127: S194S205.
  • 6
    Salem R,Lewandowski RJ,Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005; 16: 16271639.
  • 7
    Sangro B,Bilbao JI,Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 792800.
  • 8
    Anderson JH,Goldberg JA,Bessent RG, et al. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Radiother Oncol. 1992; 25: 137139.
  • 9
    Gray B,Van Hazel G,Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001; 12: 17111720.
  • 10
    Stubbs RS,Cannan RJ,Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001; 5: 294302.
  • 11
    Van Hazel G,Blackwell A,Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004; 88: 7885.
  • 12
    Lewandowski RJ,Thurston KG,Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005; 16: 16411651.
  • 13
    Lim L,Gibbs P,Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005; 35: 222227.
  • 14
    Murthy R,Xiong H,Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005; 16: 937945.
  • 15
    Popperl G,Helmberger T,Munzing W,Schmid R,Jacobs TF,Tatsch K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005; 20: 200208.
  • 16
    Welsh JS,Kennedy AS,Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: S62S73.
  • 17
    Sharma RA,Van Hazel GA,Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007; 25: 10991106.
  • 18
    Bayraktar UD,Seren S,Bayraktar Y. Hepatic venous outflow obstruction: 3 similar syndromes. World J Gastroenterol. 2007; 13: 19121927.
  • 19
    Ho S,Lau WY,Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996; 23: 947952.
  • 20
    Lemeshow S,Hosmer DWJr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982; 115: 92106.
  • 21
    Reed GBJr,Cox AJJr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol. 1966; 48: 597611.
  • 22
    Lau WY,Ho S,Leung WT,Chan M,Lee WY,Johnson PJ. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology. 2001; 48: 338340.
  • 23
    Kulik LM,Mulcahy MF,Hunter RD,Nemcek AAJr,Abecassis MM,Salem R. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl. 2005; 11: 11271131.
  • 24
    Lawrence TS,Robertson JM,Anscher MS,Jirtle RL,Ensminger WD,Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995; 31: 12371248.
  • 25
    Ogata K,Hizawa K,Yoshida M, et al. Hepatic injury following irradiation—a morphologic study. Tokushima J Exp Med. 1963; 43: 240251.
  • 26
    Rubbia-Brandt L,Audard V,Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15: 460466.
  • 27
    Wickremesekera JK,Chen W,Cannan RJ,Stubbs RS. Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with yttrium microspheres. Int J Radiat Oncol Biol Phys. 2001; 49: 10151021.
  • 28
    Campbell AM,Bailey IH,Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2001; 46: 487498.
  • 29
    Kornblum N,Ayyanar K,Benimetskaya L,Richardson P,Iacobelli M,Stein CA. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006; 16: 105114.
  • 30
    Kalayoglu-Besisik S,Yenerel MN,Caliskan Y,Ozturk S,Besisik F,Sargin D. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc. 2005; 37: 22852289.
  • 31
    Zenz T,Rossle M,Bertz H,Siegerstetter V,Ochs A,Finke J. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation—role of transjugular intrahepatic portosystemic shunt (TIPS). Liver. 2001; 21: 3136.
  • 32
    Therapondos G,Wong F. Miscellaneous indications for transjugular intrahepatic portosystemic stent-shunt. Eur J Gastroenterol Hepatol. 2006; 18: 11611166.